Bronchodilating Effect and Anabolic Effect of Inhaled Procaterol

Abstract

While the use of oral β₂-agonists by athletes is prohibited because of their anabolic effects, some inhaled β₂-agonists can be used in accordance with the World Anti-Doping Agency regulations. We examined the dose disparity between the bronchodilating effect and anabolic effect of inhaled procaterol, a selective β₂-agonist, to determine if the drug might be effective for athletes with asthma. Intact rats were given nebulized procaterol at 0.001, 0.01, 0.1 and 1 mg/mL by inhalation, and its inhibitory effect on carbachol-induced bronchoconstriction was evaluated. Castrated rats were given nebulized procaterol at 0.03, 0.1, 0.3 and 1 mg/mL by inhalation 3 times a day for 14 days, and anabolic markers (body weight gain, weight of the levator ani muscle and gastrocnemius muscle) were measured. At 0.01 mg/mL and higher, procaterol dose-dependently inhibited carbachol-induced bronchoconstriction with a significant effect. At doses of up to 0.3 mg/mL, there were no signs indicating an anabolic effect of procaterol. At 1 mg/mL, however, a slight but statistically significant increase in the weight of the levator ani muscle was observed with no significant changes in other anabolic markers. It was suggested that inhaled procaterol might be useful for athletes with asthma because of the big dose disparity between its bronchodilating effect and anabolic effect in rats.

Key words

β₂‐agonist - asthma - athlete - testosterone

References

• 1 Arai Y, Nitta K, Shida T. Evaluation of procaterol aerosol as an aerosolized β₂-adrenergic bronchodilator in conscious guinea pigs.  Jpn J Allergol. 1985;  34 999-1005
• 2 Carter W J, Lynch M E. Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats.  Metabolism. 1994;  43 1119-1125
• 3 Chen C, Ishikawa Y, Amano I, Eguchi T, Ishida H. Age-dependent changes in response of rat prostatic tissues to isoproterenol and forskolin: changes with sexual maturation in function of G proteins.  Mech Ageing Dev. 1995;  81 1-13
• 4 Choo J J, Horan M A, Little R A, Rothwell N J. Anabolic effects of clenbuterol on skeletal muscle are mediated by β₂-adrenoceptor activation.  Am J Physiol. 1992;  263 E50-E56
• 5 Hershberger L G, Shipley E G, Meyer R K. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method.  Proc Soc Exp Biol Med. 1953;  83 175-180
• 6 Himori N, Taira N. Assessment of the selectivity of OPC-2009, a new β₂-adrenoceptor stimulant, by the use of the blood-perfused trachea in situ and of the isolated blood-perfused papillary muscle of the dog.  Br J Pharmacol. 1977;  61 9-17
• 7 Howell R E, Sickels B D, Woeppel S L. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs.  J Pharmacol Exp Ther. 1993;  264 609-615
• 8 Ikezono K, Kamata M, Mori T. Adrenal influences on the inhibitory effects of procaterol, a selective beta-two-adrenoceptor agonist, on antigen-induced airway microvascular leakage and bronchoconstriction in guinea pigs.  Pharmacology. 2005;  73 209-215
• 9 Lombardo F, Sgro P, Salacone P, Gilio B, Gandini L, Dondero F, Jannini E A, Lenzi A. Androgens and fertility.  J Endocrinol Invest. 2005;  28 51-55
• 10 Moore N G, Pegg G G, Sillence M N. Anabolic effects of the β₂-adrenoceptor agonist salmeterol are dependent on route of administration.  Am J Physiol. 1994;  267 E475-E484
• 11 Navegantes L CC, Resano N MZ, Migliorini R H, Kettelhut I C. Role of adrenoceptors and cAMP on the catecholamine-induced inhibition of proteolysis in rat skeletal muscle.  Am J Physiol. 2000;  280 E663-E668
• 12 Sillence M N, Matthews M L, Spiers W G, Pegg G G, Lindsay D B. Effects of clenbuterol, ICI118551 and sotalol on the growth of cardiac and skeletal muscle and on β₂-adrenoceptor density in female rats.  Naunyn Schmiedebergs Arch Pharmacol. 1991;  344 449-453
• 13 Striegel H, Rössner D, Simon P, Niess A M. The world anti-doping code 2003 – consequences for physicians associated with elite athletes.  Int J Sports Med. 2005;  26 238-243
• 14 Tei S, Yamashita S, Yabuuchi Y. The β-adrenoceptor stimulant action of procaterol, a new β₂-adrenoceptor stimulant, on bronchial resistance and heart rate in guinea pigs.  Oyō Yakuri. 1979;  17 335-343
• 15 Yabuuchi Y. The β-adrenoceptor stimulant properties of OPC-2009 on guinea-pig isolated tracheal, right atrial and left atrial preparations.  Br J Pharmac. 1977;  61 513-521
• 16 Yabuuchi Y, Yamashita S, Tei S. Pharmacological studies of OPC-2009, a newly synthesized selective beta adrenoceptor stimulant, in the bronchomotor and cardiovascular system of the anesthetized dog.  J Pharmacol Exp Ther. 1977;  202 326-336
• 17 World Anti-Doping Agency (WADA) .The 2007 Prohibited List International Standard. www.wada-ama.org . 
• 18 World Anti-Doping Agency (WADA) .Therapeutic Use Exemptions. Abbreviated Process. www.wada-ama.org .